Home  |  Contact

UniProtKB/Swiss-Prot Q14204: Variant p.Arg598Cys

Cytoplasmic dynein 1 heavy chain 1
Gene: DYNC1H1
Variant information

Variant position:  598
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Cysteine (C) at position 598 (R598C, p.Arg598Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CMT2O and SMALED1; slight increased BICD2-binding.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  598
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  4646
The length of the canonical sequence.

Location on the sequence:   ANEMFRIFSRFNALFVRPHI  R GAIREYQTQLIQRVKDDIES
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ANEMFRIFSRFNALFVRPHIRGAIREYQTQLIQRVKDDIES

Mouse                         ANEMFRIFSRFNALFVRPHIRGAIREYQTQLIQRVKDDIES

Rat                           ANEMFRIFSRFNALFVRPHIRGAIREYQTQLIQRVKDDIES

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 4646 Cytoplasmic dynein 1 heavy chain 1
Region 53 – 1867 Stem
Region 448 – 703 Interaction with DYNC1I2
Helix 597 – 603


Literature citations

Novel mutations in the DYNC1H1 tail domain refine the genetic and clinical spectrum of dyneinopathies.
Peeters K.; Bervoets S.; Chamova T.; Litvinenko I.; De Vriendt E.; Bichev S.; Kancheva D.; Mitev V.; Kennerson M.; Timmerman V.; De Jonghe P.; Tournev I.; MacMillan J.; Jordanova A.;
Hum. Mutat. 36:287-291(2015)
Cited for: VARIANT LYS-94; VARIANT SMALED1 LEU-264; VARIANT CMT2O CYS-598; CHARACTERIZATION OF VARIANT SMALED1 LEU-264; CHARACTERIZATION OF VARIANT CMT2O CYS-598; INTERACTION WITH BICD2;

Exome Sequencing Identifies DYNC1H1 Variant Associated With Vertebral Abnormality and Spinal Muscular Atrophy With Lower Extremity Predominance.
Punetha J.; Monges S.; Franchi M.E.; Hoffman E.P.; Cirak S.; Tesi-Rocha C.;
Pediatr. Neurol. 52:239-244(2015)
Cited for: VARIANT SMALED1 CYS-598;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.